Skadden, Freshfields and Davis Polk take the lead as blockbuster Pfizer/AstraZeneca deal gears up again Jaishree Kalia28 April 2014Corporate and M&A Skadden, Arps, Slate, Meagher & Flom, Freshfields Bruckhaus Deringer and Davis Polk & Wardwell have all landed lead roles advising Pfizer and AstraZeneca as talks over a potential $100bn merger resurface.Your limit of 1 article in 30 days is up. Please login for full access or subscribe. Corporate users - click here for simple access (no password needed). For more information, please contact [email protected] Related ContentMore in this categoryTrading Places: Ropes hires Freshfields levfin co-head as top Kirkland litigator retiresFreshfields and Covington advise as Merck acquires US biotech company Terns for $6.7bnPinsents and Freshfields in the mix as Danone eats up Huel for €1bnKnights in merger talks to create £200m firmTrophy mandates and client plaudits: Weil’s London M&A team hits its strideFreshfields and Covington advise as Merck acquires US biotech company Terns for $6.7bnRevolving doors: Simpson Thacher, Latham, Sidley lead New Year London movesFive partners vie to succeed Hoyland as Simmons managing partner‘Seize every opportunity’ – Paul Hastings partner Reena Gogna on City law, Suits and poetry